Gregory S. Emch

Array ( [id] => 12728827 [patent_doc_number] => 20180134776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => Alpha-Synuclein Antibodies (4H6) [patent_app_type] => utility [patent_app_number] => 15/815354 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15815354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18171792 [patent_doc_number] => 11571485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Peptides and antibodies for detecting changes in alzheimer's disease brain and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/349531 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 21515 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16349531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728824 [patent_doc_number] => 20180134775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => Alpha-Synuclein Antibodies (7A11) [patent_app_type] => utility [patent_app_number] => 15/815316 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15815316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060138 [patent_doc_number] => 11104725 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Amyloid beta oligomer specific binding molecule [patent_app_type] => utility [patent_app_number] => 16/347927 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 13573 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17104367 [patent_doc_number] => 11124562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => Anti-ApoE antibodies [patent_app_type] => utility [patent_app_number] => 16/345637 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 126 [patent_no_of_words] => 41663 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15948675 [patent_doc_number] => 10662226 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers [patent_app_type] => utility [patent_app_number] => 15/794776 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 93 [patent_no_of_words] => 27381 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 290 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15794776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15850557 [patent_doc_number] => 10640544 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors [patent_app_type] => utility [patent_app_number] => 15/794171 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 18 [patent_no_of_words] => 45857 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15794171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649325 [patent_doc_number] => 20190231791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => Combination Therapy [patent_app_type] => utility [patent_app_number] => 16/332207 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16332207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16153553 [patent_doc_number] => 20200215009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => Optimized Solution for the Treatment of Alzheimer's, Stroke, Cardiovascular and other Amyloid Related Diseases [patent_app_type] => utility [patent_app_number] => 15/713627 [patent_app_country] => US [patent_app_date] => 2017-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15713627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531747 [patent_doc_number] => 20190201494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING NICOTINE WITHDRAWAL [patent_app_type] => utility [patent_app_number] => 16/331691 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16331691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233451 [patent_doc_number] => 20180066314 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'USE OF TRPC6 MRNA LEVELS IN PERIPHERAL BLOOD CELLS FOR EARLY DETECTION/DIAGNOSIS OF SENILE DEMENTIA' [patent_app_type] => utility [patent_app_number] => 15/699114 [patent_app_country] => US [patent_app_date] => 2017-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 11555 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15699114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328523 [patent_doc_number] => 20180215799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => METHODS FOR TREATING PSYCHIATRIC DISORDERS OR SYMPTOMS THEREOF USING NCAM PEPTIDE MIMETICS [patent_app_type] => utility [patent_app_number] => 15/697251 [patent_app_country] => US [patent_app_date] => 2017-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15697251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12231924 [patent_doc_number] => 20180064788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'TREATING NEURODEGENERATIVE DISEASES WITH PROGRANULIN' [patent_app_type] => utility [patent_app_number] => 15/688072 [patent_app_country] => US [patent_app_date] => 2017-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 20167 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15688072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12746722 [patent_doc_number] => 20180140741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => HYALURONIC ACID DERIVATIVE AND NEURAL STEM CELLS FOR SCI AND PNT REGENERATION [patent_app_type] => utility [patent_app_number] => 15/668716 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12217549 [patent_doc_number] => 20180055909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS' [patent_app_type] => utility [patent_app_number] => 15/658967 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 12895 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15658967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770882 [patent_doc_number] => 10981971 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Fusion protein for treating Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 16/304606 [patent_app_country] => US [patent_app_date] => 2017-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 6759 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15102229 [patent_doc_number] => 10472415 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Antibodies specific for hyperphosphorylated tau and methods of use [patent_app_type] => utility [patent_app_number] => 15/645442 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 28 [patent_no_of_words] => 54703 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15645442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16230575 [patent_doc_number] => 10738115 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => Humanized antibodies transmigrating the blood-brain barrier and uses thereof [patent_app_type] => utility [patent_app_number] => 16/314891 [patent_app_country] => US [patent_app_date] => 2017-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 12111 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16314891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16499854 [patent_doc_number] => 10865229 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Synthetic MBNL proteins for treatment of repeat expansion disease [patent_app_type] => utility [patent_app_number] => 16/308098 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 63 [patent_no_of_words] => 25250 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11948249 [patent_doc_number] => 20170252400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE TREATMENT OF SJÖRGREN\'S SYNDROME' [patent_app_type] => utility [patent_app_number] => 15/598216 [patent_app_country] => US [patent_app_date] => 2017-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18461 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15598216 [rel_patent_id] =>[rel_patent_doc_number] =>)